List of Omnaris drug patents
Omnaris is owned by Covis.
Omnaris contains Ciclesonide.
Omnaris has a total of 1 drug patent out of which 0 drug patents have expired.
Omnaris was authorised for market use on 20 October, 2006.
Omnaris is available in spray, metered;nasal dosage forms.
Omnaris can be used as treatment of nasal symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older. treatment of nasal symptoms associated w perennial allergic rhinitis in adults and adolescents 12 years of age and older.
The generics of Omnaris are possible to be released after 01 February, 2028.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8371292 | COVIS | Use of ciclesonide for the treatment of respiratory diseases |
Feb, 2028
(4 years from now) | |
Drugs and Companies using CICLESONIDE ingredient
Market Authorisation Date: 20 October, 2006
Treatment: Treatment of nasal symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older. treatment of nasal symptoms associated w perennial allergic rhinitis in adults and adolescents 12 years of age and older
Dosage: SPRAY, METERED;NASAL
OMNARIS family patents
6
United States
2
Japan
2
European Union
1
Portugal
1
Slovenia
1
Croatia
1
Poland
1
Australia
1
Denmark
1
Canada
1
Spain
1
Cyprus
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic